Information Provided By:
Fly News Breaks for December 12, 2019
Dec 12, 2019 | 08:13 EDT
Canaccord analyst Arlinda Lee raised her price target on Karyopharm to $22 from $18 following its presentation at the ASH conference for Xpovio. The Xpovia data showed efficacy and safety in various myelmoa regimens and indications. She remains optimistic for selinexor's prospects in myeloma and expansion into additional indications. Lee reiterated her Buy rating on Karyopharm shares.